DIABETOLOGIA

Scope & Guideline

Shaping the future of diabetes care with impactful research.

Introduction

Delve into the academic richness of DIABETOLOGIA with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0012-186x
PublisherSPRINGER
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 1965 to 2024
AbbreviationDIABETOLOGIA / Diabetologia
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES

Aims and Scopes

DIABETOLOGIA aims to provide a platform for the dissemination of high-quality research related to diabetes and its complications, focusing on innovative treatments, management strategies, and the underlying mechanisms of the disease.
  1. Diabetes Management and Treatment Innovations:
    The journal consistently publishes studies on the latest advancements in diabetes treatment, including pharmacological interventions, lifestyle modifications, and technological innovations such as continuous glucose monitoring and automated insulin delivery systems.
  2. Pathophysiology and Mechanisms of Diabetes:
    Research exploring the biological mechanisms underlying diabetes, including genetic factors, metabolic pathways, and the role of inflammation and hormones in disease progression.
  3. Diabetes Complications and Comorbidities:
    A significant focus on the long-term complications of diabetes, including cardiovascular disease, nephropathy, neuropathy, and retinopathy, with studies examining their prevalence, risk factors, and management.
  4. Nutritional and Lifestyle Interventions:
    Emphasis on the role of diet, exercise, and lifestyle changes in diabetes management, with research on dietary patterns, nutritional interventions, and their effects on glycaemic control.
  5. Health Disparities and Patient Outcomes:
    Investigations into the socioeconomic, ethnic, and demographic factors influencing diabetes management and outcomes, highlighting disparities in healthcare access and treatment efficacy.
Recent trends in DIABETOLOGIA reflect a growing interest in several emerging areas of research that are gaining traction among diabetes researchers and clinicians.
  1. Digital Health and Technology Integration:
    An increasing number of studies are focusing on the use of digital health technologies, including mobile health applications and telemedicine, to improve diabetes management and patient engagement.
  2. Gut Microbiome and Diabetes:
    Research exploring the relationship between gut microbiota and diabetes is on the rise, highlighting the role of the microbiome in metabolic health and disease progression.
  3. Personalized Medicine Approaches:
    There is a growing emphasis on personalized or precision medicine in diabetes care, with studies investigating tailored treatment plans based on individual patient characteristics, including genetic profiles.
  4. Mental Health and Diabetes Management:
    An emerging theme is the intersection of mental health and diabetes, with increased recognition of the psychological aspects of diabetes management, including diabetes distress and depression.
  5. Innovative Therapeutic Targets:
    Research is trending towards exploring novel therapeutic targets, such as incretin-based therapies, for more effective management of diabetes and its complications.

Declining or Waning

While DIABETOLOGIA maintains a broad and evolving scope, certain themes have shown a diminishing frequency in recent publications, reflecting shifts in research focus and funding priorities.
  1. Historical Perspectives on Diabetes:
    There has been a noticeable decline in papers focusing on historical analyses of diabetes treatment and management, as the field increasingly prioritizes contemporary research and future directions.
  2. Basic Research on Islet Biology:
    While still relevant, the volume of basic research specifically targeting islet biology and cellular mechanisms has decreased in favor of applied clinical research and translational studies.
  3. Pharmacogenomics in Diabetes Treatment:
    The focus on pharmacogenomic studies related to diabetes treatment has waned, likely due to a shift towards more immediate clinical applications and outcomes rather than genetic predispositions.

Similar Journals

Diabetes & Metabolism Journal

Connecting researchers to the future of endocrinology.
Publisher: KOREAN DIABETES ASSOCISSN: 2233-6079Frequency: 6 issues/year

Diabetes & Metabolism Journal, published by the Korean Diabetes Association, is a leading open-access journal dedicated to advancing the field of endocrinology, with a specific focus on diabetes and metabolism. Since its establishment in 1991, the journal has provided a robust platform for disseminating high-quality research, contributing significantly to our understanding of diabetes pathophysiology, treatment, and prevention strategies. The journal boasts an impressive impact factor, ranking in the top quartile (Q1) of its category and occupying the 28th position out of 244 in Scopus rankings, which places it in the 88th percentile among its peers. With its commitment to open access, researchers, professionals, and students globally can explore the latest findings and innovative solutions in diabetes research. The journal continues to serve as an essential resource for those dedicated to improving patient outcomes and advancing scientific knowledge in the metabolic disorders domain.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Bridging Experimental and Clinical Endocrinology
Publisher: GEORG THIEME VERLAG KGISSN: 0947-7349Frequency: 10 issues/year

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.

CURRENT DIABETES REVIEWS

Illuminating the Path in Diabetes Studies
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-3998Frequency: 9 issues/year

CURRENT DIABETES REVIEWS is a leading academic journal published by Bentham Science Publishers Ltd, dedicated to disseminating high-quality reviews and cutting-edge insights in the field of Endocrinology, Diabetes and Metabolism. Established in 1996 and actively publishing from 2005 to 2024, this journal holds a prestigious position within the academic community, evidenced by its Q2 ranking in both relevant categories for 2023 and its impactful presence in Scopus, where it ranks #83 out of 244 in Endocrinology and Diabetes and Metabolism. Despite being a subscription-based journal, it provides researchers, healthcare professionals, and students with valuable contributions that significantly advance the understanding of diabetes and related metabolic disorders. With a commitment to promoting interdisciplinary collaboration and innovation, CURRENT DIABETES REVIEWS serves as an essential resource for those seeking to stay abreast of the latest developments in diabetes research and therapies.

Current Diabetes Reports

Delivering essential knowledge for improved patient outcomes.
Publisher: CURRENT MEDICINE GROUPISSN: 1534-4827Frequency: 12 issues/year

Current Diabetes Reports is a leading academic journal published by CURRENT MEDICINE GROUP, dedicated to advancing research and clinical practices in the field of diabetes and endocrinology. With an impressive impact factor and ranked in the prestigious Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 2001 and converging years up to 2024, Current Diabetes Reports aims to disseminate high-quality, peer-reviewed research articles, reviews, and clinical studies that address the multifaceted challenges of diabetes management and treatment. As it continues to thrive within a robust international community, the journal provides critical insights that are essential for improving patient outcomes and informing public health policies in the United States and beyond.

DIABETES

Pioneering insights in diabetes and metabolism.
Publisher: AMER DIABETES ASSOCISSN: 0012-1797Frequency: 12 issues/year

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

DIABETES-METABOLISM RESEARCH AND REVIEWS

Your Gateway to Groundbreaking Metabolic Discoveries
Publisher: WILEYISSN: 1520-7552Frequency: 8 issues/year

DIABETES-METABOLISM RESEARCH AND REVIEWS, published by WILEY, is an esteemed academic journal focusing on the forefront of research in the fields of endocrinology, diabetes, and metabolism. Since its inception in 1999, this journal has become a crucial resource for researchers, professionals, and students, boasting an impressive impact factor that reflects its high citation rates and contribution to the field. With a 2023 classification of Q1 in several categories including Endocrinology and Internal Medicine, it ranks among the top journals globally, demonstrating its significant influence and authority. The journal serves as a platform for the dissemination of innovative research, reviews, and methodologies that advance understanding and treatment of metabolic disorders. By offering valuable insights and fostering collaboration within the scientific community, DIABETES-METABOLISM RESEARCH AND REVIEWS is essential reading for anyone involved in diabetes research and clinical practice.

Journal of Diabetes

Transforming diabetes care through open access scholarship.
Publisher: WILEYISSN: 1753-0393Frequency: 12 issues/year

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.

Diabetologie

Exploring novel therapeutic strategies in diabetes management.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7447Frequency: 8 issues/year

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

Diabetology & Metabolic Syndrome

Fostering breakthroughs in metabolic syndrome research.
Publisher: BMCISSN: Frequency: 1 issue/year

Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

Diabetes Mellitus

Empowering research for better diabetes care.
Publisher: ENDOCRINOLOGY RESEARCH CENTREISSN: 2072-0351Frequency: 4 issues/year

Diabetes Mellitus, published by the Endocrinology Research Centre in the Russian Federation, is an esteemed open-access journal dedicated to the field of endocrinology, diabetes, and metabolism. Since its inception in 1998, this journal has been a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address the multifaceted challenges posed by diabetes. With its current quartile ranking of Q4 in Endocrinology and the associated fields, as well as commendable involvement in the broader scope of Internal Medicine, Diabetes Mellitus plays a crucial role in enhancing clinical practices and informing innovative therapeutic strategies. The journal caters to a diverse audience of researchers, healthcare professionals, and students, particularly those seeking to expand their knowledge and improve patient outcomes in diabetes care. With a commitment to fostering scientific conversation and collaboration, Diabetes Mellitus is an invaluable resource for anyone engaged in the fight against diabetes and its complications.